# Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Study · id `cardio:ct-nct02545049` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02545049](<https://clinicaltrials.gov/study/NCT02545049>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02545049

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7352 participants.

## Technical summary

Registry record NCT02545049. Randomized; quadruple masking; primary purpose treatment. Start 2015-09-17 (actual); primary completion 2021-02-02 (actual). Results posted on 2022-04-15.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 7352 participants (enrolled count; ClinicalTrials.gov record NCT02545049, source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)
- Started: 2015-09-17 (actual) (ClinicalTrials.gov record NCT02545049, source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)
- Primary completion: 2021-02-02 (actual) (ClinicalTrials.gov record NCT02545049, source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)
- Completion: 2021-02-02 (actual) (ClinicalTrials.gov record NCT02545049, source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)
- Results first posted: 2022-04-15 (ClinicalTrials.gov record NCT02545049, source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; Ireland; Israel; Italy; Japan; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Portugal; Puerto Rico; Romania; Russia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT02545049, source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02545049-2022-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
- Acronym: FIGARO-DKD
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Finerenone (BAY94-8862)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Finerenone (`cardio:finerenone`)
- Registry intervention is a member of this class by a sourced record link: Mineralocorticoid receptor antagonists (drug class) (`cardio:mineralocorticoid-receptor-antagonists`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes (`cardio:pubmed-34449181`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial (`cardio:pubmed-34775784`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0ebcba67f32e7a9f972508935d83247de655e4b01d41d5b8fc07ba1aa549c018
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
